Jienchi Dorward

Academic Clinical Lecturer

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jienchi Dorward is an Academic Clinical Lecturer at the University of Oxford, UK. His research areas focus on HIV treatment and monitoring, including the cost and clinical flow of point-of-care urine tenofovir testing, the emergence of dolutegravir resistance, and improving interpersonal care in HIV programmes. He has also explored the impact of COVID-19 on healthcare outcomes and the perspectives of healthcare workers regarding anti-retroviral therapy delivery during the pandemic.

Articles (20)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (21)

Sarah Tonkin-Crine

University of Oxford

UNITED KINGDOM

Jienchi Dorward

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Cost and clinical flow of point‐of‐care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Improving quality of interpersonal care in HIV programmes.

High burden of human papillomavirus and premalignant cervical lesions among women starting HIV treatment in KwaZulu-Natal, South Africa.

Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic: A five-year review

Healthcare worker perspectives on adaptations to differentiated anti-retroviral therapy delivery during COVID-19 in South Africa: A qualitative inquiry

Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa.

Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER)

Point-of-Care Viral Load Testing to Manage HIV Viremia During the Rollout of Dolutegravir-Based ART in South Africa: A Randomized Feasibility Study (POwER)

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Health worker experiences of implementing TB infection prevention and control: A qualitative evidence synthesis to inform implementation recommendations

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

Differentiated service delivery for people using second‐line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu‐Natal, South Africa

Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

Collaborators (21)

Sarah Tonkin-Crine

Melissa Dobson

Philip Evans

Emma Ogburn

Oliver van Hecke

Jane Holmes

Ashley Bardon

Simon Royal

VICTORIA HARRIS

Jon Dickson

RICHARD RUSSELL

Mark Lown

Duncan Richards

Claudia Jansen van Vuuren

Azhar Zafar

Helene-Mari van der Westhuizen

Vibhore Prasad

Kerenza Hood

Haroon Ahmed

Najib M Rahman

Gail Hayward

Make your next move.